ClinicalTrials.gg
RecruitingNCT07449117Updated Mar 4, 2026

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

An interventional study of Active Temporal Interference Stimulation (TIS) and Placebo / Sham TIS in Mild Cognitive Impairment (MCI) Amnestic, Lewy Body Disease With Mild Cognitive Impairment and Parkinson's Disease With Mild Cognitive Impairment, sponsored by Masaryk University. Recruiting at 1 site in Czechia. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Masaryk University · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Cognitive Dysfunction with a site in Czechia — 10 open to participants now, 14 under way, 2 of them phase 3. Cognitive Dysfunction · Czechia.

Planned enrollment
16th of 30
70 · median 80
Started
2026
with 4 others
No phase
18 of 36
6 open now
Primary completion
2027-12
later than 10 of 13 live
Registered
34th of 36
by date
Lead sponsor
8 of 36
Masaryk University

Among the 36 studies in Cognitive Dysfunction with a site in Czechia, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 34th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

10 of the 36 studies in Cognitive Dysfunction with a site in Czechia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Cognitive Dysfunction with a site in Czechia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the immediate effects of non-invasive temporal interference stimulation (TIS) targeting the striatum on sentence processing and brain connectivity in patients with neurodegenerative diseases.

Read the detailed description

The study aims to investigate the immediate effects of non-invasive temporal interference stimulation (TIS) targeting the deep structures of the fronto-striatal circuit involved in language processing. The research focuses on patients with neurodegenerative diseases who often suffer from communication deficits and impaired sentence comprehension.

Participants will undergo a cross-over design consisting of a single session of active TIS directed at the striatum and a session of placebo stimulation. The stimulation will be administered in a randomized order. The duration of the stimulation is approximately 20 minutes. During the stimulation, participants will perform a sentence comprehension task. Resting-state fMRI measurements will be taken before and after the stimulation to evaluate offline effects on brain connectivity and potential neuroplasticity.

03

Conditions studied

  • Mild Cognitive Impairment (MCI) Amnestic
  • Lewy Body Disease With Mild Cognitive Impairment
  • Parkinson's Disease With Mild Cognitive Impairment

Keywords

  • Temporal Interference Stimulation
  • Functional Magnetic Resonance Imaging
  • Sentence Comprehension
  • Language Processing
  • Brain Connectivity
  • Striatum
  • Fronto-striatal Circuit
  • Mild Cognitive Impairment
  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Possible or probable Mild Cognitive Impairment with Lewy Bodies (MCI-LB), in Parkinson's Disease (MCI-PD) or Amnestic Mild Cognitive Impairment (aMCI).

Exclusion criteria

Exclusion Criteria:

  • Any severe psychiatric disorder.
  • History of other neurological diseases affecting the central nervous system.
  • Severe head trauma.
  • Uncompensated internal or oncological disease.
  • Presence of MRI-incompatible metal in the body (e.g., pacemaker).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Active TIS followed by Placebo TIS

    Participants first receive single-session active TIS targeting the striatum for approx. 20 minutes. Following a washout period, they receive placebo (sham) TIS.

    Device: Active Temporal Interference Stimulation (TIS) · Device: Placebo / Sham TIS

  • Experimental
    Placebo TIS followed by Active TIS

    Participants first receive single-session placebo (sham) TIS for approx. 20 minutes. Following a washout period, they receive active TIS targeting the striatum.

    Device: Active Temporal Interference Stimulation (TIS) · Device: Placebo / Sham TIS

Interventions

  • DeviceActive Temporal Interference Stimulation (TIS)

    Non-invasive brain interference stimulation applied for approximately 20 minutes while the participant performs a sentence comprehension task.

  • DevicePlacebo / Sham TIS

    Placebo stimulation applied for approximately 20 minutes while the participant performs a sentence comprehension task.

06

What researchers measure

Primary outcomes

  1. Changes in Task-Related Brain Activation

    Assessment of the immediate offline effects of the prior stimulation on brain activation in language and fronto-striatal networks. This is measured using functional magnetic resonance imaging (fMRI) during an fMRI-adapted language task immediately after the stimulation session. The Blood Oxygen Level-Dependent (BOLD) signal acquired following active TIS will be compared to the signal acquired following placebo (sham) TIS.

    Time frame: Immediately following the 20-minute stimulation session (approximately 0 to 30 minutes post-stimulation).

  2. Changes in Resting-State Functional Connectivity

    Evaluation of short-term neuroplasticity and network-level changes induced by the stimulation. Resting-state functional magnetic resonance imaging (rs-fMRI) data acquired immediately after the active TIS session will be compared to rs-fMRI data acquired after the placebo (sham) TIS session to identify changes in functional connectivity between the targeted striatum and broader cortical language networks.

    Time frame: Immediately following the 20-minute stimulation session (approximately 0 to 30 minutes post-stimulation).

  3. Behavioral Performance in Sentence Comprehension Task

    Evaluation of language processing measured by accuracy (number or percentage of correct responses) and reaction time (in milliseconds) during the Sentence Comprehension Task. This task is completed by the participant concurrently with the administration of either active Temporal Interference Stimulation (TIS) or placebo (sham) TIS outside of the MRI scanner.

    Time frame: During the approximately 20-minute stimulation intervention.

07

Study locations

1 of 1 sites recruiting
  • CEITEC MU (Central European Institute of Technology, Masaryk University)
    Brno, South Moravian 625 00, Czechia
    Recruiting
    • Ľubomíra Nováková, Ph.D. · Contactlubomira.novakova@ceitec.muni.cz · +420 549 497 766
    • Ľubomíra Nováková, Ph.D. · Principal investigator
    • Irena Rektorová, Prof. Ph.D. · Sub investigator
    • Jiří Mekyska, Ph.D. · Sub investigator
    • Jan Fousek, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The study follows Open Science and FAIR data principles, adhering to the standard of 'as open as possible, as closed as necessary.' IPD, including neuroimaging and behavioral data collected at the CEITEC MAFIL laboratory, are considered sensitive personal data. Therefore, data will be strictly anonymized. Fully anonymized participant data will be made publicly available via trusted data repositories (such as Zenodo or Figshare) and assigned a persistent identifier (DOI). For any specific datasets where full anonymization is not possible due to the sensitive nature of the data and privacy protection regulations, the raw IPD will not be shared; instead, only the metadata will be published.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The anonymized data will be stored and made available for a minimum of 5 years after the completion of the project.

Access criteria: Open access via repositories (Zenodo/Figshare) for fully anonymized data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07449117
Lead sponsor
Masaryk University
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Ľubomíra Nováková, Ph.D.
Contact
lubomira.novakova@ceitec.muni.cz
+420 549 497 766

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion